GLP-1 drugs dominate the obesity market, but Aardvark Therapeutics aims to curb appetite by going after a different target: TAS2 receptors in the gut. The biotech’s lead drug candidate is in Phase 3 testing in Prader-Willi syndrome, a genetic disorder that causes persistent hunger leading to overeating.
The post Aardvark Therapeutics’ Pursuit of New Obesity Target Adds $94M in IPO Cash appeared first on MedCity News.
